- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 15 of 15.
EudraCT Number: 2020-003874-30 | Sponsor Protocol Number: MS700568_0158 | Start Date*: 2021-02-03 | |||||||||||||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||||||||||||
Full Title: A 2-year follow-up study to assess cognition and health-related quality of life in participants with highly-active relapsing multiple sclerosis, having participated in the CLARIFY MS trial | |||||||||||||||||||||||
Medical condition: Highly-active relapsing multiple sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) DK (Completed) AT (Completed) FR (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000893-69 | Sponsor Protocol Number: BN42082 | Start Date*: 2020-10-28 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis (MS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000028-36 | Sponsor Protocol Number: P3-IMU-838-RMS-01 | Start Date*: 2022-04-21 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1) | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) GR (Completed) DE (Trial now transitioned) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003995-42 | Sponsor Protocol Number: MS700568_0157 | Start Date*: 2020-12-18 | |||||||||||||||||||||
Sponsor Name:Merck Healthcare KGaA | |||||||||||||||||||||||
Full Title: A 2-year extension study to evaluate long-term effectiveness of Mavenclad® in participants who have completed Trial MS700568_0022 (MAGNIFY MS) | |||||||||||||||||||||||
Medical condition: Highly-active relapsing multiple sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) FI (Completed) AT (Completed) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003507-38 | Sponsor Protocol Number: 218MS403 | Start Date*: 2012-01-06 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple S... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) NL (Completed) PT (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007952-90 | Sponsor Protocol Number: LT-02-UC-01 | Start Date*: 2009-11-17 | |||||||||||
Sponsor Name:Lipid Therapeutics GmbH | |||||||||||||
Full Title: A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulce... | |||||||||||||
Medical condition: Patients with ulcerative colitis (UC) according to European Crohn's and Colitis Organisation (ECCO) consensus; Simple Clinical Colitis Activity Index (SCCAI) ≥5 and SCCAI subscore for “blood in sto... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003465-38 | Sponsor Protocol Number: MS-tolDC_Phase2-RESTORE | Start Date*: 2023-05-08 | ||||||||||||||||
Sponsor Name:Antwerp University Hospital [...] | ||||||||||||||||||
Full Title: A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for multiple sclerosis | ||||||||||||||||||
Medical condition: Diagnosis of multiple sclerosis, according to the most recent diagnostic criteria | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000049-34 | Sponsor Protocol Number: ACT16753 | Start Date*: 2022-09-15 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long... | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) DE (Trial now transitioned) GR (Prematurely Ended) BG (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000368-90 | Sponsor Protocol Number: 218MS205 | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and ... | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004980-39 | Sponsor Protocol Number: Amiloride02 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis | |||||||||||||
Medical condition: Optic Neuritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004589-32 | Sponsor Protocol Number: 7724 | Start Date*: 2014-05-07 | |||||||||||
Sponsor Name:University of Southampton | |||||||||||||
Full Title: Bath Additives for the Treatment of cHildhood Eczema (BATHE) | |||||||||||||
Medical condition: Childhood Eczema | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004158-40 | Sponsor Protocol Number: P170702J | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 | |||||||||||||
Medical condition: Patients with Relapsing MS or primary progressive MS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000867-21 | Sponsor Protocol Number: NGAM-13 | Start Date*: 2021-08-16 |
Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H. | ||
Full Title: A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome | ||
Medical condition: Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). PANS is a research diagnosis given to patients who have an abrupt, dramatic onset of neuropsychiatric symptoms including obsessions/compulsio... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003361-14 | Sponsor Protocol Number: LTS6050 | Start Date*: 2007-01-23 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple... | |||||||||||||
Medical condition: Multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) FI (Completed) DE (Completed) IT (Completed) SE (Completed) NL (Completed) PT (Completed) DK (Completed) CZ (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003366-33 | Sponsor Protocol Number: 26593 | Start Date*: 2008-10-30 | |||||||||||
Sponsor Name:MERCK SERONO INTERNATIONAL SA | |||||||||||||
Full Title: A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris S... | |||||||||||||
Medical condition: MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020881-53 | Sponsor Protocol Number: 20100008 | Start Date*: 2011-01-18 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019544-39 | Sponsor Protocol Number: 20090072 | Start Date*: 2010-10-04 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
